openPR Logo
Press release

Elabscience® Announces Antibody Technology Upgrade and Product Portfolio Enhancement

11-12-2025 11:53 AM CET | Science & Education

Press release from: Elabscience

antibody technology upgrated

antibody technology upgrated

HOUSTON, Texas, November 10, 2025 - Elabscience®, a leading global biotechnology company dedicated to providing high-quality reagents and services for life science research, today announced a major technological upgrade to its antibody product line. The initiative introduces recombinant rabbit monoclonal antibody technology, representing a significant step forward in antibody innovation, production efficiency, and performance consistency.

This upgrade reflects Elabscience's continued commitment to scientific excellence and innovation, in response to the growing global demand for high-performance and highly reproducible antibody reagents.

Driving Innovation with Recombinant Antibody Technology

With the rapid advancement of recombinant antibody engineering, Elabscience has fully integrated recombinant rabbit monoclonal antibody technology into its R&D and manufacturing processes. This new platform offers outstanding specificity, batch-to-batch consistency, stability, and scalability, addressing long-standing challenges associated with traditional hybridoma-derived antibodies.

"At Elabscience, we continuously strive to improve the scientific reliability of antibody-based research," said Dr. Lan, Director of Antibody Research and Development at Elabscience®. "By introducing recombinant rabbit monoclonal antibodies, we're empowering researchers with higher-quality, more consistent, and more efficient tools to accelerate discovery in fields such as immunology, oncology, and neuroscience."

Highlights of the Technology Upgrade
1. Advanced Molecular Design
● Utilizes humanized frameworks with rabbit variable region recombination, reducing heterologous immunogenicity, ideal for long-term in vivo studies.
● Combines phage display library screening with epitope prediction algorithms, enabling the generation of high-affinity antibodies (KD < 10−9 M) against complex conformational antigens such as GPCRs and ion channels.

2. Enhanced Production Process
● Employs CHO-S suspension cell culture in serum-free media, achieving batch yields over 500 mg, a 20-fold efficiency improvement compared with traditional hybridoma methods.
● Utilizes continuous flow chromatography purification, ensuring endotoxin levels below 0.1 EU/mg and meeting rigorous standards for preclinical research.

3. Stringent Quality Control
● Performs accelerated stability testing (activity retention > 90% after 14 days at 37°C).
● All batches undergo LC-MS peptide mapping and SEC-HPLC purity testing, with monomer content ≥ 98%.

Performance Comparison

Product Type: Anti-β-actin Antibody
Rabbit Polyclonal (Old): Inter-batch CV 12-15%
Recombinant Rabbit Monoclonal (New): Inter-batch CV < 3%

Product Type: Anti-PD-1 Antibody
Rabbit Polyclonal (Old): WB detection requires 1:500 dilution
Recombinant Rabbit Monoclonal (New): WB detection possible at up to 1:5000 dilution

Product Type: Anti-GFAP Antibody
Rabbit Polyclonal (Old): Supports IHC application only
Recombinant Rabbit Monoclonal (New): Compatible with IHC/ICC/IF multiple scenarios

These performance upgrades enable greater sensitivity, reproducibility, and versatility across diverse research applications, ensuring more reliable experimental outcomes.

Commitment to Quality and Customer Partnership

Elabscience® will continue to expand its recombinant antibody portfolio across multiple research areas, including cancer biology, immunology, and neuroscience. All updates regarding the technology upgrade and new product launches will be released in real-time through the official website and email newsletters.

Researchers and distributors are encouraged to stay connected via the Elabscience® website or contact the company directly for more information.

Contact Information
Elabscience Biotechnology Inc.
🌐 www.elabscience.com
📞 Toll-free: 1-888-852-8623 Tel: 1-832-243-6086
📧 orders@elabscience.com techsupport@elabscience.com
📍 14780 Memorial Drive, Suite 105, Houston, TX 77079, USA

About Elabscience®
Elabscience® is a biotechnology company specializing in the development and production of high-quality reagents for life science research. With a mission to empower global discovery, Elabscience® provides a wide range of products including ELISA kits, antibodies, recombinant proteins, and assay kits that support researchers in immunology, oncology, metabolism, and neuroscience worldwide.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Elabscience® Announces Antibody Technology Upgrade and Product Portfolio Enhancement here

News-ID: 4265095 • Views:

More Releases from Elabscience

Elabscience achieved success in 7th SEAVSA Congress 2016
Elabscience achieved success in 7th SEAVSA Congress 2016
According to reported, Elabscience has participated in 7th South East Asia School Veterinary Association (SEAVSA) Congress 2016 and National Conference on Medical Health Sciences 2016. The 7th SEAVSA Congress 2016 was held on 13th-14th October 2016, the theme is Emerging & Reemerging Diseases in SEA: One Health Initiatives in Veterinary & Medical Education. The National Conference on Medical Health Sciences 2016 was held on 17th-18th October 2016. The exhibition has almost
Elabscience achieved success in 7th SEAVSA Congress 2016
Elabscience achieved success in 7th SEAVSA Congress 2016
According to reported, Elabscience has participated in 7th South East Asia School Veterinary Association (SEAVSA) Congress 2016 and National Conference on Medical Health Sciences 2016. The 7th SEAVSA Congress 2016 was held on 13th-14th October 2016, the theme is Emerging & Reemerging Diseases in SEA: One Health Initiatives in Veterinary & Medical Education. The National Conference on Medical Health Sciences 2016 was held on 17th-18th October 2016. The exhibition has almost
CliniSciences’s CEO Visited Elabscience to Strengthen Cooperation
CliniSciences’s CEO Visited Elabscience to Strengthen Cooperation
CliniSciences’s CEO Tushendan RASIAH visited Elabscience to discuss how to enhance collaboration. According to report, CliniSciences was founded in 1981 and it has become Elabscience’s exclusive agent in France since 2015. Tushendan RASIAH visited Elabscience’s facility, such as sales department, product department, laboratory, new office building ... During the visit, Elabscience’s manager Wang introduced Elabscience’s technology platforms, “We have established five technology platforms, including molecular biology, cell biology, protein expression, antibody

All 4 Releases


More Releases for Elabscience®

Punch!® Software Releases Punch!CAD™ SharkCAD® & ViaCAD® 15
NOVATO, Calif., December 10, 2024 - Punch!® Software, a leading software developer of Home Design and CAD titles for over 25 years, today announced the release of new Windows and Mac versions of the SharkCAD® 15 and ViaCAD® 15 family of products. This latest release encompasses a range of variants for the Windows and Macintosh platform: SharkCAD® Pro, SharkCAD®, ViaCAD® Pro, ViaCAD® 2D/3D, and ViaCAD® 2D. Punch!CAD™ products continue to provide innovative
Acetyltransferase Assay Kit Market to Expand Steadily at 6.7% by 2030 | Cayman C …
The latest report by Congruence Market Insights, titled 'Global Acetyltransferase Assay Kit Market - Size, Trends, Share, Growth, Dynamics, Competition, and Opportunity Forecast, 2023 - 2030,' provides a thorough analysis of the global Acetyltransferase Assay Kit market. The report meticulously examines both macro and micro trends, offering insights into the dynamic factors influencing the market. It encompasses a detailed exploration of qualitative and quantitative aspects, delivering a precise depiction of
Cell Counting Kit-8 Market Predicts Massive Growth by 2030 | MedChemExpress, Ela …
The latest research study released by Stratagem Market Insights on "Cell Counting Kit-8 Market" with 100+ pages of analysis on business strategy taken up by emerging industry players, geographical scope, market segments, product landscape and price, and cost structure. It also assists in market segmentation according to the industry's latest and upcoming trends to the bottom-most level, topographical markets, and key advancement from both market and technology-aligned perspectives. Each section
Elabscience achieved success in 7th SEAVSA Congress 2016
According to reported, Elabscience has participated in 7th South East Asia School Veterinary Association (SEAVSA) Congress 2016 and National Conference on Medical Health Sciences 2016. The 7th SEAVSA Congress 2016 was held on 13th-14th October 2016, the theme is Emerging & Reemerging Diseases in SEA: One Health Initiatives in Veterinary & Medical Education. The National Conference on Medical Health Sciences 2016 was held on 17th-18th October 2016. The exhibition has almost
Elabscience achieved success in 7th SEAVSA Congress 2016
According to reported, Elabscience has participated in 7th South East Asia School Veterinary Association (SEAVSA) Congress 2016 and National Conference on Medical Health Sciences 2016. The 7th SEAVSA Congress 2016 was held on 13th-14th October 2016, the theme is Emerging & Reemerging Diseases in SEA: One Health Initiatives in Veterinary & Medical Education. The National Conference on Medical Health Sciences 2016 was held on 17th-18th October 2016. The exhibition has almost
CliniSciences’s CEO Visited Elabscience to Strengthen Cooperation
CliniSciences’s CEO Tushendan RASIAH visited Elabscience to discuss how to enhance collaboration. According to report, CliniSciences was founded in 1981 and it has become Elabscience’s exclusive agent in France since 2015. Tushendan RASIAH visited Elabscience’s facility, such as sales department, product department, laboratory, new office building ... During the visit, Elabscience’s manager Wang introduced Elabscience’s technology platforms, “We have established five technology platforms, including molecular biology, cell biology, protein expression, antibody